Regarding GERN , Imetelestat proven drug cure ( now being used with FDA approval to treat dying cancer patients to prolong life ) and Telomerase. GERN has done more science in Telomerase then all other Bio's combined. TRUST JNJ's $935 Million dollar recent partnership.
Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A(abstract)
Do Yale professors (researchers) believe that this could be effective in 90% of all cancers( YES)
Over 90% of all cancer cells express telomerase,which is required for their survival. However, telomerase inhibitors alone have so far failed to provide any significant clinical benefit. Therefore identifying and targeting genes that can enhance the effects of telomerase inhibitors will greatly benefit a large population of cancer patients. We find that simultaneous inhibition of p21and telomerase synergistically suppresses tumor growth. We also show that our approach is useful for p53 mutant cancers, when used with therapies that restore the function of mutant p53. We anticipate that simultaneous targeting of p21 and telomerase will overcome the current limitation of single-agent telomerase therapeutics and provide an effective method to treat cancers that rely on telomerase activity for survival.
As posted on the GERN message board by author Hay.
I own JNJ at $42 a share. Been Berry Berry Good to me. As have GILD REGN KITE OPK BLUE and BIIB to name a few. Now its time for little known GERN to make the grade of the above .
When you have time please check out GERN and the GERON web site. JNJ's $935 million partnership signed in December 2014 for a Proven and now being administered to patients Imetelestat will change the future for 90% of all cancer drugs.
Don't trust me , trust JNJ . GO GERN and GO JNJ.
Getting a bit greedy aren't we ?
JNJ has raised the dividend 53 years in a row.
Considering what the banks are willing to pay, a 5.7% hike is fine by me
geez a bunch of crybabies... I bought this at 80 and it is at 100 now pays a pretty good dividend...just wait..it will go higher...very good company.... an elephant in the field of health care....hjalmarson
Bullish expectation surrounds PRKI as management confirms major deal with major player in the outdoor digital advertising space. Can the stock rally past $1?
I thought all the old school "Weldon Bashers" died. Guess not. Damn cockroaches. They never all die.
JNJ, Employees, Investors, Society continue to pay the price for the Weldon/McCoy missteps. What a disaster. How's Avon doing....revenues down 44%! Ethicon Women's Health/Tylenol Quality issues still linger. Weldon even sued the Red Cross! But he walked away with 100's of millions in his pocket. Never forget!
Sentiment: Strong Buy
Zacks raises GERN to a rank of #2 in light of the $935 Million dollar partnership with JNJ along with the vast potentials for GERNs proven cancer cure Imetelestat.
Don't trust me! Trust Janssen and JNJ knew exactly what they were doing when they signed this great partnership in December . 2014 with GERN.
For additional information go to Geron corps web site to learn more about this amazing partnership with Janssen / JNJ.
Geron Shares Could Double
As the biotech makes moves to restore market confidence, shares could reach $6 in one year.
March 5, 2015
Geron (GERN: Nasdaq) By MLV & Co. ($2.81, March 5, 2015)
We are raising our one-year price target from $4.25 to $6.00 and reiterate our Buy rating for Geron based on two new imetelstat indications that are accretive to our new discounted-cash-flow model.
Based on Geron’s (ticker: GERN) market valuation prior to a temporary clinical hold in 2014 (now fully resolved), we think Geron’s opportunity to overtake Incyte (INCY) in...
Go JNJ and Go GERN . JNJ 's 935 million dollar investment in a pioneering break through cancer cure Imetelestat will see both JNJ and GERN making huge profits going forward.
Amag with PE of @ 6 is climbing. It has been shorted around 30% of float, so be careful if you jump in. I've made a small bet just in case the climb continues. Not sure but it's posdible a mother of all Short Squeezes is in progress?????
Interesting thought! My broker recommended J & J and G E to me last week. I'm trying to get out of income producing stocks. Randy in Wisconsin
That would be extremely disappointing if indeed that were the dividend increase. That would represent merely a 5.7% hike and it would mark the second straight year of a 6% or lower dividend hike, which would be quite disappointing. I think at the least the company should raise its dividend to $0.75 per quarter or $3.00 annually, which would be just over the 7% mark. That would represent a very fair, reasonable hike. $3.00 a share would also be far lower than free cash flow per share and earnings per share, so again I think it would be a proportionate, reasonable hike.
.74 would be unacceptable IMO.